Company / SG&A Expense
Kymera Therapeutics, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$68.2M
FY2025
5-year range
$8.0M / $68.2M
FY2021-FY2025
Trend
+7.3%
vs FY2024
Sector context
#135 of 213
Health Care
What the data says
At $68M, Kymera Therapeutics, Inc.'s sg&a expense ranks #79 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $8M in FY2021 to $68M in FY2025.
Based on SEC 10-K filings.
$68M in FY2025 with a 5-year CAGR of +53.6%.
Increased from $55M to $68M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.9%
- 5-Year CAGR
- +53.6%
- 10-Year CAGR
- -
Sector benchmark
#79 of 213 in Health CareTop 37% of 213This company $68.2M Sector average $722.3M
▼
-90.6% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +53.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 7.3% year-over-year.
- Ranks #135 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.2M | +7.3% |
| FY2024 | $63.5M | +15.4% |
| FY2023 | $55.0M | +25.6% |
| FY2022 | $43.8M | +449.2% |
| FY2021 | $8.0M | +0.0% |
| FY2020 | $8.0M | +0.0% |
| FY2019 | $8.0M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026